>Marché de l'imagerie des essais cliniques en Asie-Pacifique, par produit et services (services et logiciels), modalité ( tomodensitométrie , imagerie par résonance magnétique, échocardiographie, médecine nucléaire, tomographie par émission de positons , rayons X, ultrasons, tomographie par cohérence optique et autres), application (oncologie, neurologie, endocrinologie, cardiologie, dermatologie, hématologie et autres), utilisateur final (sociétés pharmaceutiques et biotechnologiques, organismes de recherche sous contrat, fabricants de dispositifs médicaux, instituts de recherche universitaires et gouvernementaux et autres), distributeur (ventes directes et ventes par appel d'offres) - Tendances et prévisions de l'industrie jusqu'en 2029.
Analyse et perspectives du marché de l'imagerie des essais cliniques en Asie-Pacifique
La demande croissante en technologie d'imagerie, suivie de l'augmentation de la prévalence des maladies chroniques en raison de l'augmentation de la population âgée et des initiatives stratégiques des acteurs du marché telles que le lancement de produits, l'avancement, l'acquisition et les accords sont les facteurs qui devraient stimuler la croissance du marché.
Toutefois, des scénarios de remboursement inappropriés et défavorables pour les appareils d’imagerie et l’absence de normes bien définies dans les instruments d’imagerie des essais cliniques devraient freiner la croissance du marché.
Les progrès technologiques croissants dans l'imagerie des essais cliniques pour le diagnostic et le traitement des maladies chroniques devraient stimuler la croissance du marché. Data Bridge Market Research analyse que le marché de l'imagerie des essais cliniques en Asie-Pacifique connaîtra un TCAC de 8,8 % au cours de la période de prévision de 2022 à 2029.
|
Rapport métrique |
Détails |
|
Période de prévision |
2022 à 2029 |
|
Année de base |
2021 |
|
Années historiques |
2020 (personnalisable jusqu'en 2019-2014) |
|
Unités quantitatives |
Chiffre d'affaires en millions USD et prix en USD |
|
Segments couverts |
Par produit et services (services et logiciels), modalité (tomodensitométrie, imagerie par résonance magnétique, échocardiographie, médecine nucléaire, tomographie par émission de positons, rayons X, ultrasons, tomographie par cohérence optique et autres), application (oncologie, neurologie, endocrinologie, cardiologie, dermatologie, hématologie et autres), utilisateur final (sociétés pharmaceutiques et biotechnologiques, organismes de recherche sous contrat, fabricants de dispositifs médicaux, instituts de recherche universitaires et gouvernementaux et autres), distributeur (ventes directes et ventes par appel d'offres) |
|
Pays couverts |
Chine, Japon, Corée du Sud, Inde, Australie, Singapour, Thaïlande, Malaisie, Indonésie, Philippines et reste de l'Asie-Pacifique |
|
Acteurs du marché couverts |
Navitas Life Sciences, Resonance Health Analytical Services, ICON plc, Image Core Lab, Radiant Sage LLC, WORLDCARE CLINICAL, Clario, Paraxel International Corporation, Median Technologies, Perspectum, Calyx, WIRB-Copernicus Group et Invicro.LLC, entre autres |
Définition du marché
Clinical trial is a process of developing new drugs. It is designed for potential treatment and its effects on humans. Before the commercialization of new drugs, extensive clinical testing is done to identify promising compounds and safety tests are conducted to determine the possible risks.
In clinical trials, medical imaging plays a significant role in more accurate and effective results. Different imaging technologies may be used to elucidate and demonstrate the mechanistic actions of drugs. Clinical trial imaging is the process of clinical analysis and medical intervention by creating image representations of inner parts of the body. It has several different technologies which are used to view the human body to monitor, treat and diagnose medical conditions.
In the coming future, important decisions related to clinical trial imaging on drug discovery will be made by individuals who not only understand the biopsy but can also use the clinical trial imaging tools and the knowledge they release to develop hypotheses and identify quality targets.
Asia-Pacific Clinical Trial Imaging Market Dynamics
Drivers
- Rising R&D Expenditure
Imaging and pharma companies are continuously investing in R&D to offer innovative services for clinical trial imaging to customers and enhance their market presence. Medical imaging plays a dynamic role in clinical development. While the medical imaging industry is in a constant state of fluctuation due to implementation of new technologies in the market, the pharmaceutical and imaging industries continue to increase. This is attributed to enhanced investment in medical imaging companies along with mergers and acquisitions as well as the adoption of innovation in imaging technologies to support clinical trials for medical devices. Increasing R&D expenditure in pharmaceutical and biotechnological companies is fuelling market growth.
This has encouraged the development of new products and high research-oriented programs organized in biopharmaceutical industries and a high preference for the studies of human genome. Rising expenditure on R&D activities also develops new drugs and therapies to treat chronic diseases that boost market growth. This helps the pharmaceutical and biotechnological companies in the development of new technologies in the category of imaging clinical trials therefore, rising R&D expenditure is expected to drive the market growth.
- Increasing Number of Contract Research Organizations (CROs)
Contract Research Organization (CRO) is an organization that gives support for clinical trials and other research services to imaging and pharmaceutical industries in the form of outsourced pharmaceutical research services in terms of both drugs and medical devices. CRO helps imaging and pharmaceutical industries with the drug development process to reduce the cost and initiate the process of bringing clinical trials to develop the drug for a particular disease segment by using clinical trial imaging and other processes to overcome capacity gaps of the in-house research team for pharmaceutical and clinical research.
A huge number of CROs are engaged in monitoring the drug development process such as PAREXEL (U.S.), PRA Health Sciences (U.S.), Labcorp (U.S.), PPD (U.S.), Syneos Health (U.S.), ICON plc (Ireland), Envigo (U.K.), Charles River (U.S.) and SGS (Switzerland) among others. These are some CROs that are engaged to give support for clinical trials and other research services to the imaging and pharmaceutical industries. The increasing number of CROs is expected to drive market growth.
Opportunities
- Rise in Healthcare Expenditure
Healthcare expenditure has increased across the world as people's disposable income in various countries is increasing. Moreover, to accomplish the population requirements, government bodies and healthcare organizations are taking the initiative by virtue of accelerating healthcare expenditure.
For instance,
- National Health Expenditure Accounts (NHEA) published a report which stated that the U.S. healthcare expenditure grew by 4.6% in 2019. This estimates USD 3.80 trillion for the overall U.S. population reported by U.S. Centers for Medicare (CMS) and GDP health, spending in the U.S. is accounted to reach 17.7%.
Growing healthcare expenditure is also beneficial for further growth in the economic and healthcare sector and it is primarily fruitful as it significantly affects the development of better and advanced medical products in the market. Therefore, the surge in healthcare expenditure is expected to create a greater opportunity for the market.
- Strategic Initiatives by Market Players
The demand for clinical trial imaging is increasing in the market owing to the increased levels of R&D along with the growth of clinical trial imaging market aided by the desire for innovative medications. Thus, the top market players have implemented a new strategy by developing new products and collaborating with other market players to improve business operations and profitability.
For instance,
- In February 2020, ICON plc acquired MedPass International, a European medical devices CRO, reimbursement and regulatory consultancy. This acquisition has reportedly helped in the expansion of the medical device and diagnostic research services of ICON in Europe.
These strategic initiatives by the market players, including acquisition, conferences and focused segment product launches, are helping them grow and improve the company's product portfolio, ultimately leading to more revenue generation. Hence, these strategic initiatives by the market players may act as an opportunity for market growth.
Restraints/Challenges
- High-Risk Radiation Causing Diseases
In clinical medical imaging, radiation is absorbed by the body which can harm molecular structures inside the patient’s body. High doses of radiation can affect human cells including loss of hair, skin burns and increased incidence of cancer. The estimated risk of developing fatal cancer is one in 2000 after going through a radiation dose of 10 mSv in a CT scan.
For instance,
- According to Radiological Society of America (RSNA), 1% to 2% of all cancers in the U.S. are caused by CT scans and the American Cancer Society identified CT scans and X-rays as one of the reasons for breast cancer, brain cancer and other cancers
- According to the Center for Disease Control and Prevention, exposure to high levels of radiation results in acute radiation syndrome. The amount of radiation that a person's body absorbs is called the radiation dose.
The high-risk radiation that occurs, would decrease the usage and sale of clinical trial imaging devices, thereby affecting the credibility of manufacturers involved in this market. Therefore, the high-risk radiation-causing diseases are expected to restrain the market growth.
- Strict Regulatory Policies
The healthcare industry is regulated by a structure of laws, rules & regulations that are extensive and complex.
For instance,
- In April 2018, the U.S. FDA released updated Guidance for Clinical Trial Imaging Endpoint Process Standards for the industry which includes the quality of imaging data obtained in clinical trials
- Biotechnology and pharmaceutical industries need to take first approval from the FDA for the process of drug development. They have to submit an Investigational New Drug (IND) application to the FDA before beginning clinical research.
COVID-19 Impact on the Asia-Pacific Clinical Trial Imaging Market
Diagnostic imaging services have been time-consuming and complicated by the need for strict infection control and prevention practices developed to contain the risk of transmission and protect healthcare personnel. Hence, the decision to image suspected patients or COVID-19-positive patients is based on their impact on the improvement of patient status. There have definitely been reduced volumes in outpatient medical imaging clinics due to social distancing regulations and lockdowns in Asia-Pacific region. This reduced the available appointments which led to longer waiting lists for exams such as ultrasound and interventional procedures.
Recent Developments
- En janvier 2022, Clario s'est associé à XingImaging, une société de production de produits radiopharmaceutiques et d'acquisition de tomographie par émission de positons (TEP), pour réaliser des essais cliniques d'imagerie TEP afin de tester de nouvelles thérapies en Chine. Le partenariat propose de partager les ressources communes et les experts en neurosciences de Clario et de XingImaging pour accélérer le démarrage des essais cliniques et la découverte de médicaments en Chine.
- En novembre 2021, Clario a été créée. ERT et Bioclinica ont fusionné pour former Clario. La création d'une nouvelle société a donné lieu à la distribution de logiciels et de services d'imagerie clinique et à une augmentation des ventes.
Portée du marché de l'imagerie des essais cliniques en Asie-Pacifique
Le marché de l'imagerie des essais cliniques en Asie-Pacifique est segmenté en cinq segments en fonction des produits et services, des modalités, des applications, des utilisateurs finaux et des distributeurs. La croissance de ces segments vous aidera à analyser les segments de croissance limités dans les industries et à fournir aux utilisateurs un aperçu précieux du marché et des informations sur le marché pour les aider à prendre des décisions stratégiques pour identifier les principales applications du marché.
Produits et services
- Services
- Logiciel
En fonction des produits et des services, le marché est segmenté en services et logiciels.
Modalité
- Tomodensitométrie
- Imagerie par résonance magnétique
- Échocardiographie
- Médecine nucléaire
- Tomographie par émission de positons
- radiographie
- Ultrason
- Tomographie par cohérence optique
- Autres
En fonction de la modalité, le marché est segmenté en tomodensitométrie , imagerie par résonance magnétique , échocardiographie, médecine nucléaire, tomographie par émission de positons, rayons X, ultrasons, tomographie par cohérence optique et autres.
Application
- Oncologie
- Neurologie
- Cardiologie
- Endocrinologie
- Dermatologie
- Hématologie
- Autres
En fonction des applications, le marché est segmenté en oncologie , neurologie, cardiologie, endocrinologie, dermatologie, hématologie et autres.
Utilisateur final
- Organismes de recherche sous contrat
- Sociétés pharmaceutiques et biotechnologiques
- Fabricants de dispositifs médicaux
- Instituts de recherche universitaires et gouvernementaux
- Autres
En fonction de l'utilisateur final, le marché est segmenté en organismes de recherche sous contrat , sociétés pharmaceutiques et biotechnologiques, fabricants de dispositifs médicaux, instituts de recherche universitaires et gouvernementaux et autres.
Distributeur
- Vente directe
- Ventes par appel d'offres
En fonction du distributeur, le marché est segmenté en ventes directes et ventes par appel d'offres.
Analyse/perspectives régionales du marché de l'imagerie des essais cliniques en Asie-Pacifique
Le marché de l’imagerie des essais cliniques en Asie-Pacifique est analysé et des informations sur la taille du marché et les tendances sont fournies par régions, produits et services, modalité, application, utilisateur final et distributeur comme référencé ci-dessus.
Les pays couverts par ce rapport de marché sont la Chine, le Japon, la Corée du Sud, l'Inde, l'Australie, Singapour, la Thaïlande, la Malaisie, l'Indonésie, les Philippines et le reste de l'Asie-Pacifique. La Chine devrait dominer le marché car l'imagerie clinique est sûre et pratique à utiliser. Le rôle vital du gouvernement chinois dans la mise en place et l'établissement de fournisseurs nationaux dans le domaine de l'imagerie diagnostique en Chine est l'un des principaux facteurs qui devraient stimuler la croissance du marché.
La section par pays du rapport fournit également des facteurs individuels ayant un impact sur le marché et des changements dans la réglementation du marché national qui ont un impact sur les tendances actuelles et futures du marché. Des points de données tels que les nouvelles ventes, les ventes de remplacement, la démographie du pays, l'épidémiologie des maladies et les tarifs d'importation et d'exportation sont quelques-uns des principaux indicateurs utilisés pour prévoir le scénario du marché pour les différents pays. En outre, la présence et la disponibilité des marques d'Asie-Pacifique et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des marques locales et nationales sur les canaux de vente sont prises en compte lors de l'analyse prévisionnelle des données par pays.
Analyse du paysage concurrentiel et des parts de marché de l'imagerie des essais cliniques en Asie-Pacifique
Le paysage concurrentiel du marché de l'imagerie des essais cliniques en Asie-Pacifique fournit des détails sur le concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements en R&D, les nouvelles initiatives du marché, la présence en Asie-Pacifique, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit et la domination des applications. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises liées au marché de l'imagerie des essais cliniques en Asie-Pacifique.
Certains des principaux acteurs opérant sur le marché sont Navitas Life Sciences, Resonance Health Analytical Services, ICON plc, Image Core Lab, Radiant Sage LLC, WORLDCARE CLINICAL, Clario, Paraxel International Corporation, Median Technologies, Perspectum, Calyx, WIRB-Copernicus Group et Invicro.LLC entre autres.
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCTS AND SERVICES LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
5 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET: REGULATIONS
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISING R&D EXPENDITURE
6.1.2 INCREASING NUMBER OF CONTRACT RESEARCH ORGANIZATIONS (CROS)
6.1.3 INCREASING INCIDENCE OF CHRONIC DISEASES
6.1.4 GROWTH IN THE PHARMACEUTICAL AND IMAGING INDUSTRIES
6.2 RESTRAINTS
6.2.1 HIGH-RISK RADIATION CAUSING DISEASES
6.2.2 HIGH IMPLEMENTATION COST OF IMAGING SYSTEMS
6.3 OPPORTUNITIES
6.3.1 RISE IN HEALTHCARE EXPENDITURE
6.3.2 STRATEGIC INITIATIVES BY KEY PLAYERS
6.3.3 DEVELOPMENT OF INNOVATIVE IMAGING MODALITIES AND CONTRAST AGENTS
6.4 CHALLENGES
6.4.1 STRICT REGULATORY POLICIES
6.4.2 COST OF CLINICAL TRIALS
7 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET, BY PRODUCTS & SERVICES
7.1 OVERVIEW
7.2 SERVICES
7.2.1 OPERATIONAL IMAGING SERVICES
7.2.2 READ ANALYSIS SERVICES
7.2.3 TRIAL DESIGN CONSULTING SERVICES
7.2.4 SYSTEM AND TECHNICAL SUPPORT SERVICES
7.3 SOFTWARE
8 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET, BY MODALITY
8.1 OVERVIEW
8.2 COMPUTED TOMOGRAPHY
8.3 MAGENTIC RESONANCE IMAGING
8.4 ECHOCARDIOGRAPHY
8.5 NUCLEAR MEDICINE
8.6 POSITRON EMISSION TOMOGRAPHY
8.7 X-RAY
8.8 ULTRASOUND
8.9 OPTICAL COHERENCE TOMOGRAPHY
8.1 OTHERS
9 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET, BY APPLICATION
9.1 OVERVIEW
9.2 ONCOLOGY
9.2.1 X-RAY
9.2.2 ULTRASOUND
9.2.3 COMPUTED TOMOGRAPHY
9.2.4 MAGNETIC RESONANCE IMAGING
9.2.5 NUCLEAR MEDICINE
9.2.6 POSITRON EMISSION TOMOGRAPHY
9.2.7 OPTICAL COHERENCE TOMOGRAPHY
9.2.8 ECHOCARDIOGRAPHY
9.2.9 OTHERS
9.3 NEUROLOGY
9.3.1 COMPUTED TOMOGRAPHY
9.3.2 MAGNETIC RESONANCE IMAGING
9.3.3 POSITRON EMISSION TOMOGRAPHY
9.3.4 NUCLEAR MEDICINE
9.3.5 X-RAY
9.3.6 ULTRASOUND
9.3.7 OPTICAL COHERENCE TOMOGRAPHY
9.3.8 ECHOCARDIOGRAPHY
9.3.9 OTHERS
9.4 CARDIOLOGY
9.4.1 ECHOCARDIOGRAPHY
9.4.2 MAGNETIC RESONANCE IMAGING
9.4.3 COMPUTED TOMOGRAPHY
9.4.4 POSITRON EMISSION TOMOGRAPHY
9.4.5 NUCLEAR MEDICINE
9.4.6 X-RAY
9.4.7 ULTRASOUND
9.4.8 OPTICAL COHERENCE TOMOGRAPHY
9.4.9 OTHERS
9.5 ENDOCRINOLOGY
9.5.1 COMPUTED TOMOGRAPHY
9.5.2 MAGNETIC RESONANCE IMAGING
9.5.3 ECHOCARDIOGRAPHY
9.5.4 POSITRON EMISSION TOMOGRAPHY
9.5.5 NUCLEAR MEDICINE
9.5.6 X-RAY
9.5.7 ULTRASOUND
9.5.8 OPTICAL COHERENCE TOMOGRAPHY
9.5.9 OTHERS
9.6 DERMATOLOGY
9.6.1 ULTRASOUND
9.6.2 X-RAY
9.6.3 MAGNETIC RESONANCE IMAGING
9.6.4 COMPUTED TOMOGRAPHY
9.6.5 OPTICAL COHERENCE TOMOGRAPHY
9.6.6 POSITRON EMISSION TOMOGRAPHY
9.6.7 NUCLEAR MEDICINE
9.6.8 ECHOCARDIOGRAPHY
9.6.9 OTHERS
9.7 HEMATOLOGY
9.7.1 ULTRASOUND
9.7.2 COMPUTED TOMOGRAPHY
9.7.3 MAGNETIC RESONANCE IMAGING
9.7.4 X-RAY
9.7.5 POSITRON EMISSION TOMOGRAPHY
9.7.6 NUCLEAR MEDICINE
9.7.7 OPTICAL COHERENCE TOMOGRAPHY
9.7.8 ECHOCARDIOGRAPHY
9.7.9 OTHERS
9.8 OTHERS
10 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET, BY END USER
10.1 OVERVIEW
10.2 CONTRACT RESEARCH ORGANIZATION
10.3 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
10.4 MEDICAL DEVICE MANUFACTURERS
10.5 ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES
10.6 OTHERS
11 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET, BY DISTRIBUTOR
11.1 OVERVIEW
11.2 DIRECT SALES
11.3 TENDER SALES
12 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET, BY REGION
12.1 ASIA-PACIFIC
12.1.1 CHINA
12.1.2 JAPAN
12.1.3 SOUTH KOREA
12.1.4 INDIA
12.1.5 AUSTRALIA
12.1.6 SINGAPORE
12.1.7 THAILAND
12.1.8 MALAYSIA
12.1.9 INDONESIA
12.1.10 PHILIPPINES
12.1.11 REST OF ASIA-PACIFIC
13 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET: COMPANY LANDSCAPE
13.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC
14 SWOT ANALYSIS
15 COMPANY PROFILE
15.1 NAVITAS LIFE SCIENCES
15.1.1 COMPANY SNAPSHOT
15.1.2 COMPANY SHARE ANALYSIS
15.1.3 PRODUCT PORTFOLIO
15.1.4 RECENT DEVELOPMENTS
15.2 RESONANCE HEALTH ANALYTICAL SERVICES
15.2.1 COMPANY SNAPSHOT
15.2.2 REVENUE ANALYSIS
15.2.3 COMPANY SHARE ANALYSIS
15.2.4 PRODUCT PORTFOLIO
15.2.5 RECENT DEVELOPMENT
15.3 CLARIO
15.3.1 COMPANY SNAPSHOT
15.3.2 COMPANY SHARE ANALYSIS
15.3.3 PRODUCT PORTFOLIO
15.3.4 RECENT DEVELOPMENTS
15.4 PARAXEL
15.4.1 COMPANY SNAPSHOT
15.4.2 COMPANY SHARE ANALYSIS
15.4.3 PRODUCT PORTFOLIO
15.4.4 RECENT DEVELOPMENT
15.5 BIOTELEMETRY, A PHILIPS COMPANY
15.5.1 COMPANY SNAPSHOT
15.5.2 COMPANY SHARE ANALYSIS
15.5.3 PRODUCT PORTFOLIO
15.5.4 RECENT DEVELOPMENT
15.6 ICON PLC
15.6.1 COMPANY SNAPSHOT
15.6.2 REVENUE ANALYSIS
15.6.3 PRODUCT PORTFOLIO
15.6.4 RECENT DEVELOPMENTS
15.7 MEDIAN TECHNOLOGIES
15.7.1 COMPANY SNAPSHOT
15.7.2 REVENUE ANALYSIS
15.7.3 PRODUCT PORTFOLIO
15.7.4 RECENT DEVELOPMENT
15.8 PERSPECTUM
15.8.1 COMPANY SNAPSHOT
15.8.2 PRODUCT PORTFOLIO
15.8.3 RECENT DEVELOPMENTS
15.9 ANAGRAM 4 CLINICAL TRIALS
15.9.1 COMPANY SNAPSHOT
15.9.2 PRODUCT PORTFOLIO
15.9.3 RECENT DEVELOPMENT
15.1 CALYX
15.10.1 COMPANY SNAPSHOT
15.10.2 PRODUCT PORTFOLIO
15.10.3 RECENT DEVELOPMENT
15.11 IMAGE CORE LAB
15.11.1 COMPANY SNAPSHOT
15.11.2 PRODUCT PORTFOLIO
15.11.3 RECENT DEVELOPMENT
15.12 INVICRO. LLC. (A SUBSIDIARY OF KONICA MINOLTA)
15.12.1 COMPANY SNAPSHOT
15.12.2 REVENUE ANALYSIS
15.12.3 PRODUCT PORTFOLIO
15.12.4 RECENT DEVELOPMENTS
15.13 IXICO PLC
15.13.1 COMPANY SNAPSHOT
15.13.2 REVENUE ANALYSIS
15.13.3 PRODUCT PORTFOLIO
15.13.4 RECENT DEVELOPMENTS
15.14 QUOTIENT SCIENCES
15.14.1 COMPANY SNAPSHOT
15.14.2 PRODUCT PORTFOLIO
15.14.3 RECENT DEVELOPMENT
15.15 RADIANT SAGE LLC
15.15.1 COMPANY SNAPSHOT
15.15.2 PRODUCT PORTFOLIO
15.15.3 RECENT DEVELOPMENT
15.16 WIRB-COPERNICUS GROUP
15.16.1 COMPANY SNAPSHOT
15.16.2 PRODUCT PORTFOLIO
15.16.3 RECENT DEVELOPMENT
15.17 WORLDCARE CLINICAL
15.17.1 COMPANY SNAPSHOT
15.17.2 PRODUCT PORTFOLIO
15.17.3 RECENT DEVELOPMENT
16 QUESTIONNAIRE
17 RELATED REPORTS
Liste des tableaux
TABLE 1 COST OF CLINICAL TRIAL PHASE 2 AND PHASE 3
TABLE 2 HUGE R&D COST IN THE U.S. FOR DIFFERENT PHASES
TABLE 3 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET, BY PRODUCTS & SERVICES, 2020-2029 (USD MILLION)
TABLE 4 ASIA PACIFIC SERVICES IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 5 ASIA PACIFIC SERVICES IN CLINICAL TRIAL IMAGING MARKET, BY PRODUCTS & SERVICES, 2020-2029 (USD MILLION)
TABLE 6 ASIA PACIFIC SOFTWARE IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 7 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2020-2029 (USD MILLION)
TABLE 8 ASIA PACIFIC COMPUTED TOMOGRAPHY IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 9 ASIA PACIFIC MAGNETIC RESONANCE IMAGING IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 10 ASIA PACIFIC ECHOCARDIOGRAPHY IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 11 ASIA PACIFIC NUCLEAR MEDICINE IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 12 ASIA PACIFIC POSITRON EMISSION TOMOGRAPHY IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 13 ASIA PACIFIC X-RAY IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 14 ASIA PACIFIC ULTRASOUND IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 15 ASIA PACIFIC OPTICAL COHERENCE TOMOGRAPHY IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 16 ASIA PACIFIC OTHERS IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 17 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 18 ASIA PACIFIC ONCOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 ASIA PACIFIC ONCOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 20 ASIA PACIFIC NEUROLOGY IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 21 ASIA PACIFIC NEUROLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 22 ASIA PACIFIC CARDIOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 23 ASIA PACIFIC CARDIOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 24 ASIA PACIFIC ENDOCRINOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 25 ASIA PACIFIC ENDOCRINOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 26 ASIA PACIFIC DERMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 27 ASIA PACIFIC DERMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 28 ASIA PACIFIC HEMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 29 ASIA PACIFIC HEMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 30 ASIA PACIFIC OTHERS IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 31 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 32 ASIA PACIFIC CONTRACT RESEARCH ORGANIZATION IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 33 ASIA PACIFIC PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 34 ASIA PACIFIC MEDICAL DEVICE MANUFACTURERS IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 35 ASIA PACIFIC ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 36 ASIA PACIFIC OTHERS IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 37 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET, BY DISTRIBUTOR, 2020-2029 (USD MILLION)
TABLE 38 ASIA PACIFIC DIRECT SALES IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 39 ASIA PACIFIC TENDER SALES IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 40 ASIA-PACIFIC CLINICAL TRIAL IMAGING MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 41 ASIA-PACIFIC CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)
TABLE 42 ASIA-PACIFIC SERVICES IN CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)
TABLE 43 ASIA-PACIFIC CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2020-2029 (USD MILLION)
TABLE 44 ASIA-PACIFIC CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 45 ASIA-PACIFIC ONCOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 46 ASIA-PACIFIC NEUROLOGY CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 47 ASIA-PACIFIC ENDOCRINOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION,2020-2029 (USD MILLION)
TABLE 48 ASIA-PACIFIC CARDIOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 49 ASIA-PACIFIC DERMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 50 ASIA-PACIFIC HEMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 51 ASIA-PACIFIC CLINICAL TRIAL IMAGING MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 52 ASIA-PACIFIC CLINICAL TRIAL IMAGING MARKET, BY DISTRIBUTOR, 2020-2029 (USD MILLION)
TABLE 53 CHINA CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)
TABLE 54 CHINA SERVICES IN CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)
TABLE 55 CHINA CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2020-2029 (USD MILLION)
TABLE 56 CHINA CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 57 CHINA ONCOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 58 CHINA NEUROLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 59 CHINA ENDOCRINOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 60 CHINA CARDIOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 61 CHINA DERMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 62 CHINA HEMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 63 CHINA CLINICAL TRIAL IMAGING MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 64 CHINA CLINICAL TRIAL IMAGING MARKET, BY DISTRIBUTOR, 2020-2029 (USD MILLION)
TABLE 65 JAPAN CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)
TABLE 66 JAPAN SERVICES IN CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)
TABLE 67 JAPAN CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2020-2029 (USD MILLION)
TABLE 68 JAPAN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 69 JAPAN ONCOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 70 JAPAN NEUROLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 71 JAPAN ENDOCRINOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 72 JAPAN CARDIOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 73 JAPAN DERMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 74 JAPAN HEMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 75 JAPAN CLINICAL TRIAL IMAGING MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 76 JAPAN CLINICAL TRIAL IMAGING MARKET, BY DISTRIBUTOR, 2020-2029 (USD MILLION)
TABLE 77 SOUTH KOREA CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)
TABLE 78 SOUTH KOREA SERVICES IN CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)
TABLE 79 SOUTH KOREA CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2020-2029 (USD MILLION)
TABLE 80 SOUTH KOREA CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 81 SOUTH KOREA ONCOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 82 SOUTH KOREA NEUROLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 83 SOUTH KOREA ENDOCRINOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 84 SOUTH KOREA CARDIOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 85 SOUTH KOREA DERMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 86 SOUTH KOREA HEMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 87 SOUTH KOREA CLINICAL TRIAL IMAGING MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 88 SOUTH KOREA CLINICAL TRIAL IMAGING MARKET, BY DISTRIBUTOR, 2020-2029 (USD MILLION)
TABLE 89 INDIA CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)
TABLE 90 INDIA SERVICES IN CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)
TABLE 91 INDIA CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2020-2029 (USD MILLION)
TABLE 92 INDIA CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 93 INDIA ONCOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 94 INDIA NEUROLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 95 INDIA ENDOCRINOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 96 INDIA CARDIOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 97 INDIA DERMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 98 INDIA HEMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 99 INDIA CLINICAL TRIAL IMAGING MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 100 INDIA CLINICAL TRIAL IMAGING MARKET, BY DISTRIBUTOR, 2020-2029 (USD MILLION)
TABLE 101 AUSTRALIA CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)
TABLE 102 AUSTRALIA SERVICES IN CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)
TABLE 103 AUSTRALIA CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2020-2029 (USD MILLION)
TABLE 104 AUSTRALIA CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 105 AUSTRALIA ONCOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 106 AUSTRALIA NEUROLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 107 AUSTRALIA ENDOCRINOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 108 AUSTRALIA CARDIOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 109 AUSTRALIA DERMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 110 AUSTRALIA HEMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 111 AUSTRALIA CLINICAL TRIAL IMAGING MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 112 AUSTRALIA CLINICAL TRIAL IMAGING MARKET, BY DISTRIBUTOR, 2020-2029 (USD MILLION)
TABLE 113 SINGAPORE CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)
TABLE 114 SINGAPORE SERVICES IN CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)
TABLE 115 SINGAPORE CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2020-2029 (USD MILLION)
TABLE 116 SINGAPORE CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 117 SINGAPORE ONCOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 118 SINGAPORE NEUROLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 119 SINGAPORE ENDOCRINOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 120 SINGAPORE CARDIOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 121 SINGAPORE DERMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 122 SINGAPORE HEMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 123 SINGAPORE CLINICAL TRIAL IMAGING MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 124 SINGAPORE CLINICAL TRIAL IMAGING MARKET, BY DISTRIBUTOR, 2020-2029 (USD MILLION)
TABLE 125 THAILAND CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)
TABLE 126 THAILAND SERVICES IN CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)
TABLE 127 THAILAND CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2020-2029 (USD MILLION)
TABLE 128 THAILAND CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 129 THAILAND ONCOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 130 THAILAND NEUROLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 131 THAILAND ENDOCRINOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 132 THAILAND CARDIOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 133 THAILAND DERMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 134 THAILAND HEMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 135 THAILAND CLINICAL TRIAL IMAGING MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 136 THAILAND CLINICAL TRIAL IMAGING MARKET, BY DISTRIBUTOR, 2020-2029 (USD MILLION)
TABLE 137 MALAYSIA CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)
TABLE 138 MALAYSIA SERVICES IN CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)
TABLE 139 MALAYSIA CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2020-2029 (USD MILLION)
TABLE 140 MALAYSIA CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 141 MALAYSIA ONCOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 142 MALAYSIA NEUROLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 143 MALAYSIA ENDOCRINOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 144 MALAYSIA CARDIOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 145 MALAYSIA DERMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 146 MALAYSIA HEMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 147 MALAYSIA CLINICAL TRIAL IMAGING MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 148 MALAYSIA CLINICAL TRIAL IMAGING MARKET, BY DISTRIBUTOR, 2020-2029 (USD MILLION)
TABLE 149 INDONESIA CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)
TABLE 150 INDONESIA SERVICES IN CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)
TABLE 151 INDONESIA CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2020-2029 (USD MILLION)
TABLE 152 INDONESIA CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 153 INDONESIA ONCOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 154 INDONESIA NEUROLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 155 INDONESIA ENDOCRINOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 156 INDONESIA CARDIOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 157 INDONESIA DERMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 158 INDONESIA HEMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 159 INDONESIA CLINICAL TRIAL IMAGING MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 160 INDONESIA CLINICAL TRIAL IMAGING MARKET, BY DISTRIBUTOR, 2020-2029 (USD MILLION)
TABLE 161 PHILIPPINES CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)
TABLE 162 PHILIPPINES SERVICES IN CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)
TABLE 163 PHILIPPINES CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2020-2029 (USD MILLION)
TABLE 164 PHILIPPINES CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 165 PHILIPPINES ONCOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 166 PHILIPPINES NEUROLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 167 PHILIPPINES ENDOCRINOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 168 PHILIPPINES CARDIOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 169 PHILIPPINES DERMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 170 PHILIPPINES HEMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 171 PHILIPPINES CLINICAL TRIAL IMAGING MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 172 PHILIPPINES CLINICAL TRIAL IMAGING MARKET, BY DISTRIBUTOR, 2020-2029 (USD MILLION)
TABLE 173 REST OF ASIA-PACIFIC CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)
Liste des figures
FIGURE 1 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET: SEGMENTATION
FIGURE 2 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET: DATA TRIANGULATION
FIGURE 3 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET: DROC ANALYSIS
FIGURE 4 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET: ASIA PACIFIC VS REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET: DBMR MARKET POSITION GRID
FIGURE 8 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 9 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET: SEGMENTATION
FIGURE 11 THE INCREASING NUMBER OF CONTRACT RESEARCH ORGANIZATION AND RISING R&D EXPENDITURE ARE EXPECTED TO DRIVE THE ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 SERVICES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET IN 2022 & 2029
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET
FIGURE 14 WORLDWIDE BIOPHARMA COMPANIES R&D EXPENDITURE (IN USD MILLION)
FIGURE 15 THE MARKET GROWTH IN CLINICAL CRO (IN USD MILLIONS)
FIGURE 16 THE FUNCTION OF CRO
FIGURE 17 ESTIMATED NEW CANCER CASES, 2022
FIGURE 18 VALUE OF THE PHARMACEUTICAL SECTOR, WORLDWIDE, 2021 BY COUNTRY (IN MILLION U.S. DOLLARS)
FIGURE 19 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET: BY PRODUCTS & SERVICES, 2021
FIGURE 20 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET: BY PRODUCTS & SERVICES, 2022-2029 (USD MILLION)
FIGURE 21 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET: BY PRODUCTS & SERVICES, CAGR (2022-2029)
FIGURE 22 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET: BY PRODUCTS & SERVICES, LIFELINE CURVE
FIGURE 23 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET: BY MODALITY, 2021
FIGURE 24 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET: BY MODALITY, 2022-2029 (USD MILLION)
FIGURE 25 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET: BY MODALITY, CAGR (2022-2029)
FIGURE 26 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET: BY MODALITY, LIFELINE CURVE
FIGURE 27 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET: BY APPLICATION, 2021
FIGURE 28 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET: BY APPLICATION, 2022-2029 (USD MILLION)
FIGURE 29 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET: BY APPLICATION, CAGR (2022-2029)
FIGURE 30 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 31 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET: BY END USER, 2021
FIGURE 32 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET: BY END USER, 2022-2029 (USD MILLION)
FIGURE 33 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET: BY END USER, CAGR (2022-2029)
FIGURE 34 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET: BY END USER, LIFELINE CURVE
FIGURE 35 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET: BY DISTRIBUTOR, 2021
FIGURE 36 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET: BY DISTRIBUTOR, 2022-2029 (USD MILLION)
FIGURE 37 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET: BY DISTRIBUTOR, CAGR (2022-2029)
FIGURE 38 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET: BY DISTRIBUTOR, LIFELINE CURVE
FIGURE 39 ASIA-PACIFIC CLINICAL TRIAL IMAGING MARKET SNAPSHOT (2021)
FIGURE 40 ASIA-PACIFIC CLINICAL TRIAL IMAGING MARKET: BY COUNTRY (2021)
FIGURE 41 ASIA-PACIFIC CLINICAL TRIAL IMAGING MARKET: BY COUNTRY (2022 & 2029)
FIGURE 42 ASIA-PACIFIC CLINICAL TRIAL IMAGING MARKET: BY COUNTRY (2021 & 2029)
FIGURE 43 ASIA-PACIFIC CLINICAL TRIAL IMAGING MARKET: BY PRODUCT & SERVICES (2022-2029)
FIGURE 44 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET: COMPANY SHARE 2021 (%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.
